Literature DB >> 2953862

Binding of (+)PHNO and other D2-dopamine agonists to D1-dopamine receptors labelled by [3H]SCH 23390.

D J Pettibone, J A Totaro, B V Clineschmidt.   

Abstract

The affinity of (+)PHNO for the D1-dopamine receptor subtype in striatal tissue was determined in a radioligand binding assay using the D1-selective compound, [3H]SCH 23390. The IC50 for (+)PHNO was 22 microM, a value considerably higher than obtained for reference agents (lisuride, apomorphine, pergolide, [-] EOE and bromocriptine). The low potency of (+)PHNO at the D1-receptor subtype contrasts with the compound's high potency at the D2-receptor subtype, as reported previously. (+)PHNO can, therefore, be classified as a very selective D2-receptor agonist.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953862     DOI: 10.1007/bf01244105

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  11 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum.

Authors:  P H Andersen; F C Grønvald; J A Jansen
Journal:  Life Sci       Date:  1985-11-25       Impact factor: 5.037

3.  (+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.

Authors:  F J Grandas Perez; P G Jenner; M Nomoto; S Stahl; N P Quinn; J D Parkes; P Critchley; C D Marsden
Journal:  Lancet       Date:  1986-04-19       Impact factor: 79.321

4.  Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum.

Authors:  W Billard; V Ruperto; G Crosby; L C Iorio; A Barnett
Journal:  Life Sci       Date:  1984-10-29       Impact factor: 5.037

5.  Binding of [3H]SCH23390 in rat brain: regional distribution and effects of assay conditions and GTP suggest interactions at a D1-like dopamine receptor.

Authors:  D W Schulz; E J Stanford; S W Wyrick; R B Mailman
Journal:  J Neurochem       Date:  1985-11       Impact factor: 5.372

6.  (+)-4-Propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism.

Authors:  A J Stoessl; E Mak; D B Calne
Journal:  Lancet       Date:  1985-12-14       Impact factor: 79.321

7.  Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].

Authors:  G E Martin; M Williams; D J Pettibone; G G Yarbrough; B V Clineschmidt; J H Jones
Journal:  J Pharmacol Exp Ther       Date:  1984-09       Impact factor: 4.030

8.  The role of D-1 and D-2 receptors.

Authors:  M Schachter; P Bédard; A G Debono; P Jenner; C D Marsden; P Price; J D Parkes; J Keenan; B Smith; J Rosenthaler; R Horowski; R Dorow
Journal:  Nature       Date:  1980-07-10       Impact factor: 49.962

9.  Potent dopamine agonist activity of a novel ergoline, 6-ethyl-9-oxaergoline (EOE).

Authors:  G E Martin; M Williams; B V Clineschmidt; G G Yarbrough; J H Jones; D R Haubrich
Journal:  Life Sci       Date:  1982-05-24       Impact factor: 5.037

10.  Dopaminergic mechanisms in the teleost retina. I. Dopamine-sensitive adenylate cyclase in homogenates of carp retina; effects of agonists, antagonists, and ergots.

Authors:  K J Watling; J E Dowling
Journal:  J Neurochem       Date:  1981-02       Impact factor: 5.372

View more
  3 in total

1.  Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  C E Clarke; S Boyce; M A Sambrook; S M Stahl; A R Crossman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

2.  Endocrine and neurochemical effects of (+)-PHNO, a dopamine D2 agonist.

Authors:  C M Gust; S K Hemrick-Luecke; R W Fuller
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

3.  Action of intravenously administered talipexole on the rat striatal neurons receiving excitatory input from nigral dopamine neurons.

Authors:  H Matsubayashi; T Amano; Y Hongjing; Y Kohno; M Sasa
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.